HBV Forum: Intrahepatic Panel Webinar

Thursday, September 24, 2020
Introduction & HBV Forum Update

Jessica Weber
Forum for Collaborative Research
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderators</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 AM ET</td>
<td>Begin</td>
<td>Anuj Gaggar, Gilead Sciences, Adam Gehring, TGHRI</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Welcome and Introduction</td>
<td>Jessica Weber, Forum for Collaborative Research</td>
</tr>
<tr>
<td>11:05 AM</td>
<td>Presentations:</td>
<td>Ray Chung, Harvard Medical School, Joe Balestreri, Ashwin Balagopal, Johns Hopkins University, Mala Maini, University College London, Oscar Carrasco-Zevallos, PathAI, Stephanie Buchholz, Federal Institute of Drugs and Medical Devices, Kathleen Whitaker, U.S. Food and Drug Administration (TBC)</td>
</tr>
<tr>
<td>12:20 PM</td>
<td>Discussion</td>
<td>All</td>
</tr>
<tr>
<td>1:00 PM ET</td>
<td>Adjourn</td>
<td>All</td>
</tr>
</tbody>
</table>
HBV Forum 7- Intrahepatic Panel Webinar

- You will be muted on entry

- Discussion will take place after the presentations

- To ask questions or make a comment:
  - If generally applicable to the session, please use the Zoom chat function and send to everyone
  - Or use the raise your hand function

- For specific issues or technical questions:
  - Zoom Chat **Technical Assistance**
Rules of the [Zoom] Room

- **Presentations, discussions, comments, and questions are not for attribution**
  - Participants speak as individuals and express views that may not represent those of their organizations
  - Recording by participants is not permitted. Slides will be available on our website pending speaker permission.

- **Participation Reminder (Forum Operating Principles)**
  - We restrict industry participation to experts with the necessary scientific knowledge from organizations or entities with a clear commitment to advancing the diagnostic and therapeutic field of the disease area of the project they participate in. Only in this way can we achieve the effectiveness and productivity needed to add value to the field. The Forum is not a venue for marketing and/or investment experts.
HBV Forum 7- Intrahepatic Panel Webinar

- The Intrahepatic Panel Webinar will include presentations from various stakeholder perspectives related to digital technology, biopsies and FNAs.

- This is the second in a series of three webinars designed to replace the in-person HBV Forum 7 meeting.

- The final HBV Forum 7 webinar will feature follow-up from several HBV Forum 6 sessions and we will keep you updated as we organize ongoing HBV Forum web meetings.
Overview of the HBV Forum

- **What:** a platform for ongoing multi-stakeholder dialogue to identify barriers, prioritize research and identify solutions to accelerate therapeutic development for HBV

- **How:** provide a neutral, independent, safe space for discussion and deliberation across stakeholder groups
  - Focus on developing consensus, increasing synergy and collaboration, and reducing duplication and uncertainty
  - Ongoing working group activity throughout the year anchored by larger project events
  - Active & engaged participation

![Diagram of the HBV Forum](image)

- Regulatory Agencies
- Industry
- Patients/Community
- Foundation/Consortia
- Academic/Clinical Researchers
- Professional Societies

HBV Forum
HBV Forum Steering Committee

**Co-Chairs**
- Anuj Gaggar
  Gilead Sciences, Inc.
- Harry Janssen
  University Health Network
  Toronto Centre for Liver Disease
- Veronica Miller
  Forum for Collaborative Research
- Chari Cohen
  Hepatitis B Foundation
- Michael Ninburg
  Hepatitis Education Project
- Su Wang
  Saint Barnabas Medical Center & World Hepatitis Alliance
- Markus Comberg
  EASL
- Anna Lok
  AASLD

**Patient Advocates**
- Chari Cohen
  Hepatitis B Foundation
- Michael Ninburg
  Hepatitis Education Project
- Su Wang
  Saint Barnabas Medical Center & World Hepatitis Alliance
- Markus Comberg
  EASL
- Anna Lok
  AASLD

**Foundations**
- Tim Block
  Hepatitis B Foundation
- Peter Revill
  ICE-HBV
- Stephanie Buchholz
  Federal Institute of Drugs and Medical Devices
- Eric Donaldson
  U.S. Food & Drug Administration
- Poonam Mishra
  U.S. Food & Drug Administration
- Gabriel Westman
  Swedish Medical Products Agency

**Societies**
- Anna Lok
  AASLD
HBV Forum Steering Committee

Academics

Kosh Agarwal
King’s College Hospital

Carol L. Brosgart
University of California, San Francisco

Henry L.Y. Chan
The Chinese University of Hong Kong

Jordan Feld
Toronto Western Hospital Liver Center

Robert Fontana
University of Michigan

Adam Gehring
University of Toronto

Robert Gish
Loma Linda University Health

Seng Gee Lim
National University of Singapore

Marion Peters
University of California, San Francisco

Norah Terrault
Keck Medicine at University of Southern California

Teresa Wright
GlaxoSmithKline

Fabien Zoulim
INSERM

Industry

Maria Beumont-Mauviel
Janssen

Gavin Cloherty
Abbott Diagnostics

Wolfgang Jessner
F. Hoffmann-La Roche AG

Hema Kapoor
Quest Diagnostics

Oliver Lenz
Janssen Pharmaceuticals ID&V

Ed Marins
Roche Molecular Systems

Patricia Mendez
Immunocore

Christos Petropoulos
Monogram Biosciences
HBV Forum Working Groups

- **Immune Monitoring Working Group** - ACTIVE
  - Co-chairs: Adam Gehring, PhD and Patricia Mendez
  - Aim: Identify immune biomarker(s) that predict I) effective viral control and/or II) toxicity in therapies including immune-based interventions.

- **CAM Nomenclature Working Group** - ACTIVE
  - Aim: To create a joint statement on behalf of both the HBV Forum and ICE-HBV regarding how to standardize CAM nomenclature and promote consensus within the field.

- **Treatment Combination Working Group** - ONGOING
  - Co-chairs: Prof. Lim Seng Gee, MD and Bruce Given, MD.
  - Aims: I.) Provide clarity on the requirements of novel agents in clinical development, and II.) identify mechanisms to speed up the development of combinations of different promising agents across companies.

- **Liver Safety Monitoring sub Working Group** - ONGOING
  - Co-chairs: Robert Fontana, MD and Maria Beumont-Mauviel, MD
  - Aim: To facilitate HBV drug development by developing consensus terminology and definitions for industry, regulators, and investigators to use when testing the safety and efficacy of novel therapeutic agents for chronic HBV when used alone or in combination with other investigational or approved anti-HBV agents.
HBV Forum Working Groups

- **Surrogate Endpoints Working Group** - COMPLETED
  - Co-chairs: Marion Peters, MD and Oliver Lenz, PhD.
  - Aim: Strengthen the link of surrogate markers (endpoint in clinical studies) with long term clinical outcomes (e.g., liver disease progression, HCC).

- **Diagnostics/Biomarkers Working Group** - COMPLETED
  - Co-chairs: Ed Marins, MD and Gavin Cloherty, PhD.
  - Aim: Develop clarity on what is needed for biomarker acceptance and validation for HBV drug/diagnostic development.
HBV Forum Sponsors
HBV Forum Sponsors